Please assess the completion status of the following clinical trial:

Trial Title: A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 (or as required by local regulation).~* Histological or cytological confirmation of advanced/metastatic ALK+ NSCLC.~* Pretreated with up to three prior lines of an ALK TKI treatment, including at least one prior line of a second or third-generation ALK TKI (alectinib, brigatinib, ensartinib, or lorlatinib) in Phase 1.~* ECOG performance status ≤ 1.~* Existence of measurable or evaluable disease (according to Response evaluation criteria in solid tumors \[RECIST v1.1\] criteria).~* Subjects with asymptomatic CNS metastases and/or asymptomatic leptomeningeal carcinomatosis are eligible.~* Adequate organ function.~Exclusion Criteria:~* Major surgery within four weeks of the start of TPX-0131 treatment.~* Clinically significant cardiovascular disease~* Any of the following cardiac criteria:~  * Mean resting corrected QT interval (QTc) \> 470 msec obtained from three ECGs and any factors that increase the risk of QTc prolongation or arrhythmic events~ * Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG~* Known clinically significant active infections not controlled with systemic treatment (bacterial, fungal, viral including HIV positivity).~* Gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.~* Subjects being treated with or anticipating the need for treatment with strong CYP3A4 inhibitors or inducers.~* Subjects with current or anticipated need for drugs that are sensitive CYP2C9 substrates with narrow therapeutic indices.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TPX-0131 (Type: EXPERIMENTAL): The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0131.

Based on this trial design, predict the completion outcome and termination type (if applicable).